Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: Results from a randomized controlled trial-Reference-Cited by-同舟云学术

Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: Results from a randomized controlled trial

Published:2014-05-20 Issue:11 Volume:135 Page:2612-2622
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Zhu Feng-Cai¹,Chen Wen²,Hu Yue-Mei¹,Hong Ying³,Li Juan⁴,Zhang Xun²,Zhang Yi-Ju¹,Pan Qin-Jing²,Zhao Fang-Hui²,Yu Jia-Xi⁵,Zhang Yan-Shu⁶,Yang Xiaoping⁷,Zhang Cheng-Fu⁸,Tang Haiwen⁹,Zhang Helen¹⁰,Lebacq Marie¹¹,David Marie-Pierre¹¹,Datta Sanjoy K¹¹,Struyf Frank¹¹,Bi Dan¹¹,Descamps Dominique¹¹,

Affiliation:

1. Jiangsu Province Center for Disease Prevention and Control; Nanjing China

2. Cancer Institute and Hospital; Chinese Academy of Medical Sciences (CICAMS) and Peking Union Medical College; Beijing China

3. The Affiliated Drum Tower Hospital of Nanjing University Medical School; Nanjing Jiangsu province China

4. National Institutes for Food and Drug Control; Beijing China

5. Xuzhou Center for Disease Prevention and Control; Xuzhou Jiangsu Province China

6. Binhai Center for Disease Prevention and Control; Binhai Jiangsu Province China

7. Jintan Center for Disease Prevention and Control; Jintan Jiangsu Province China

8. Lianshui Center for Disease Prevention and Control; Lianshui Jiangsu Province China

9. GlaxoSmithKline Vaccines; Shanghai China

10. GlaxoSmithKline; Beijing China

11. GlaxoSmithKline Vaccines; Wavre Belgium

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ijc.28897/fullpdf

Reference35 articles.

1. Ferlay J Shin HR Bray F 2010 http://globocan.iarc.fr

2. Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies;Zhao;Int J Cancer,2012

3. Human papillomavirus type-distribution in the cervix of Chinese women: a meta-analysis;Bao;Int J STD AIDS,2008

4. Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18;Chen;Cancer Causes Control,2009

5. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication;Li;Int J Cancer,2011

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prospective, multi-center post-marketing surveillance cohort study to monitor the safety of the human papillomavirus-16/18 AS04-adjuvanted vaccine in Chinese girls and women aged 9 to 45 years, 2018–2020;Human Vaccines & Immunotherapeutics;2023-12

2. Comparative efficacy of human papillomavirus vaccines: systematic review and network meta-analysis;Expert Review of Vaccines;2023-11-27

3. Effectiveness and cost-effectiveness of human papillomavirus vaccination strategies among men who have sex with men in China: a modeling study;Frontiers in Immunology;2023-06-22

4. A feasibility assessment of real‐world data capabilities for monitoring vaccine safety and effectiveness in China: Human papillomavirus vaccination in the Yinzhou district as a use case;Pharmacoepidemiology and Drug Safety;2023-06-15

5. Safety and immunogenicity of a pichia pastoris-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine in healthy Chinese women aged 9–45 years: A randomized, double-blind, placebo-controlled phase 1 clinical trial;Vaccine;2023-05